Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
LUMOS PHARMA, INC. (NLNK) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting"
08/09/2023 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update",
"Second Quarter 2023 Financial Results"
06/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma Announces Departure of Chief Medical Officer"
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting"
05/03/2023 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates",
"First Quarter 2023 Financial Results"
03/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology"
03/01/2023 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates",
"Full Year 2022 Financial Results"
02/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD"
12/12/2022 8-K Quarterly results
11/30/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD"
11/14/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
04/11/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD"
03/10/2022 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials",
"Full Year 2021 Financial Results"
11/03/2021 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates",
"Third Quarter 2021 November 3, 2021 2 Forward Looking Statements This"
08/23/2021 8-K Quarterly results
08/05/2021 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates",
"Second Quarter 2021 Financial Results Presentation"
08/03/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer"
08/02/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President"
07/21/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Lumos Pharma Announces Clinical Updates"
06/28/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
04/21/2021 8-K Quarterly results
04/14/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy